BioSpace News Archive

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three years.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the first quarter 2024, before market open on Thursday, May 2, 2024.

Electromed, Inc., a leader in innovative airway clearance technologies, announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the 2024 Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 17-18, 2024.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar’s common stock on April 1, 2024, the grant date of the award.

IBEX Technologies Inc. announces that it has completed the sale of the company by amalgamating with 15720273 Canada Inc., a newly-incorporated wholly-owned subsidiary of BBI Solutions OEM Limited.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes.

Seegene Inc. announced that Prof. Dame Jenny Harries, Chief Executive of the UK Health Security Agency, visited its headquarters located in Seoul Korea, on March 27.

Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company developing multispecifics™ in oncology, and Glenmark Pharmaceuticals Ltd., shared preclinical data for its oncology asset ISB 2001 during the oral presentation at the annual American Association for Cancer Research (AACR) 2024.

Hinge Bio, Inc. today announced that Daniel Capon , Ph.D., Chief Scientific Officer are presenting data from the company’s GEM-DIMER program targeting B cell depletion at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.

AffyImmune Therapeutics, Inc today announced the formation of a Clinical and Regulatory Advisory Board (CRAB), comprised of distinguished experts in cancer research, immunology, and CAR T therapy.